摘要
目的:探讨CYP2C9和VKORC1基因多态性对房颤患者华法林稳定剂量的影响,建立适合汉族人群老年房颤患者的华法林给药模型,指导华法林个体化抗凝治疗。方法:对200例口服华法林抗凝的老年患者进行CYP2C9和VKORC1基因分型,比较不同基因型房颤患者华法林日均稳定剂量的差异。采用多元线性回归分析法依据CYP2C9和VKORC1基因型、年龄、身高、体质量、合并用药建立华法林稳定剂量计算公式。结果:INR稳定在2.0～3.0之间时,CYP2C9*1/*1基因型患者日均使用华法林剂量(3.87±0.71)mg显著高于CYP2C9*3基因型患者(1.05±0.59)mg;VKORC1-1639AA基因型患者日均使用华法林剂量(2.94±1.03)mg显著低于VKORC1-1639GA/GG基因型患者(5.76±1.12)mg。通过多元线性回归分析得出华法林稳定剂量公式,建立的回归模型中包含年龄、体质量、合并用药、CYP2C9*3和VKORC1-1639基因型,该模型能解释约56.5%个体间华法林剂量差异。结论:基于CYP2C9和VKORC1基因多态性建立的华法林稳定剂量预测公式,能帮助指导华法林在老年房颤患者中的抗凝治疗。
OBJECTIVE To investigate the effect of CYP2 C9 and VKORC1 polymorphisms on the stable dose of warfarin in patients with atrial fibrillation,and to establish a warfarin administration model suitable for elderly patients in Han population to guide warfarin individualized anticoagulant therapy.METHODS 200 warfarin-treated elderly patients with atrial fibrillation were genotyped according to CYP2 C9 and VKORC1,and then compared the daily stable doses of warfarin in these patients with different genotypes.A multiple linear regression analysis was used to establish a warfarin stabilizing dose formula based on CYP2 C9 and VKORC1 genotypes,age,height,weight,and drug combination.RESULTS When INR was stable between2.0 and 3.0,the average daily warfarin dose in patients with CYP2 C9 *1/*1 genotype(3.87±0.71)mg was significantly higher than that in patients with CYP2 C9 *3 genotype(1.05±0.59)mg;the average daily warfarin dose in patients with VKORCl-1639 AA genotype(2.94±1.03)mg was significantly lower than that in patients with VKORCl-1639 GA/GG genotype(5.76±1.12)mg.Warfarin stabilizing dose formula was obtained by multiple linear regression analysis.The established regression model include age,weight,drug combination,CYP2 C9 *3 and VKORCl-1639 genotypes.This model could explain about 56.5%individual warfarin dose difference.CONCLUSION The warfarin stabilizing dose formula established based on CYP2 C9 and VKORC1 polymorphisms can help guide the use of warfarin in elderly patients with atrial fibrillation.
引文
[1] Burn J,Pirmohamed M.Direct oral anticoagulants versus warfarin:is new always better than the old?[J].Open Heart,2018,5(1):e000712.
[2] Chinese Society of Cardiology.China Expert Consensus for Warfarin Anticoagulation Therapy[J].Chin J Intern Med(中华内科杂志),2013,52(1):76-81.
[3] Johnson JA,Caudle KE,Gong L,et al.Clinical Pharmacogenetics Implementation Consortium(CPIC)Guideline for Pharmacogenetics-Guided Warfarin Dosing:2017Update[J].Clin Pharmacol Ther,2017,102(3):397-404.
[4] Huang SW,Chen HS, Wang XQ,et al.Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose:aprospective study in Chinese patients[J].Pharmacogenet Genom,2009,19(3):226-234.
[5] Wen MS,Lee M,Chen JJ,et al.Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes[J].Clin Pharmacol Ther,2008,84(1):83-89.
[6] Fauchier L,Philippart R,Clementy N, et al.How to define valvular atrial fibrillation?[J].Arch Cardiovasc Dis,2015,108(10):530-539.
[7] Wei M,Ye F,Xie D,et al.A new algorithm to predict warfarin dose from polymorphisms of CYP4F2,CYP2C9 and VKORC1 and clinical variables:derivation in Han Chinese patients with non valvular atrial fibrillation[J].Thromb Haemost,2012,107(6):1083-1091.
[8] Cen HJ,Zeng WT,Leng XY,et al.CYP4F2rs2108622:a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement[J].Br J Clin Pharmacol,2010,70(2):234-240.
[9] Lee MT,Chen CH,Chou CH, et al.Genetic determinants of warfarin dosing in the Han-Chinese population[J].Pharmacogenomics,2009,10(12):1905-1113.
[10]Zhong SL,Yu XY,Liu Y,et al.Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients[J].Pharmacogenet Genom,2012,22(3):176-182.
[11]Groen-Wijnberg M,van Dijk J,Krauwinkel W,et al.Pharmacokinetic Interactions Between Mirabegron and Metformin,Warfarin,Digoxin or Combined Oral Contraceptives[J].Eur J Drug Metab Pharmacokinet,2017,42(3):417-429.
[12]Lupercio F,Romero J,Peltzer B,et al.Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation[J].Am J Med,2017,pii:S0002-9343(17)31283-31284.
[13]Andersson ML1,Lindh JD,Mannheimer B.The impact of interacting drugs on dispensed doses of warfarin in the Swedish population:A novel use of population based drug registers[J].J Clin Pharmacol,2013,53(12):1322-1327.
